Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04045171
Other study ID # XY3-IIT-TAC1905A01
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date August 10, 2019
Est. completion date December 31, 2020

Study information

Verified date August 2019
Source The Third Xiangya Hospital of Central South University
Contact ZHIJUN HUANG, Dr.
Phone 073188618339
Email huangzj@csu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will use a multi-center, prospective design, with a "Real World Study" model, to include 200 patients with nephrotic syndrome. based on the Population Pharmacokinetics (PPK) model, it will study genotype and clinical factors in patients with nephrotic syndrome, to explore the Pharmacokinetics/ Pharmacodynamics (PK/PD) relationship of Tacrolimus in patients with nephrotic syndrome, and develop an optimal medication regimen.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date December 31, 2020
Est. primary completion date July 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- (1)Patients with Nephrotic Syndrome:

1. Proteinuria greater than 3.5 g/24 hour

2. Serum albumin <30 g/l

3. Clinical evidence of peripheral oedema

4. Hyperlipidemia 1) and 2) are necessary for diagnosis.

- (2)18—75years old(include 75),gender is not limited;

- (3)Voluntary signing informed consent?

Exclusion Criteria:

- (1)Secondary nephrotic syndrome;

- (2)Allergic to Tacrolimus or other unsuitable use of Tacrolimus;

- (3)With other immunosuppressive agents such as cyclosporin A, cyclophosphamide, mycophenolate mofetil, leflunomide, tripterygium wilfordii (hormone is not restricted);

- (4)Severe liver dysfunction (transaminase > 3 ULN, or bilirubin > 3 ULN);

- (5)Severe renal insufficiency(eGFR<30 ml/min/1.73m2)

- (6)Joined other clinical trials within 1 month;

- (7)Missing clinical data;

- (8)Pregnancy, lactation or planning for pregnancy within 12 months;

- (9)Researchers believe that patients who are not suitable for this clinical trial?

Study Design


Intervention

Drug:
Tacrolimus
Tacrolimus, oral, 0.05-0.075 mg/kg/d, Q12h, 6~12 months

Locations

Country Name City State
n/a

Sponsors (4)

Lead Sponsor Collaborator
The Third Xiangya Hospital of Central South University First People's Hospital of Chenzhou, Hunan Provincial People's Hospital, ZhuZhou Central Hospital

References & Publications (3)

Hao GX, Huang X, Zhang DF, Zheng Y, Shi HY, Li Y, Jacqz-Aigrain E, Zhao W. Population pharmacokinetics of tacrolimus in children with nephrotic syndrome. Br J Clin Pharmacol. 2018 Aug;84(8):1748-1756. doi: 10.1111/bcp.13605. Epub 2018 May 22. — View Citation

Lu T, Zhu X, Xu S, Zhao M, Huang X, Wang Z, Zhao L. Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome. Pharm Res. 2019 Feb 4;36(3):45. doi: 10.1007/s11095-019-2579-6. — View Citation

Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient. Kidney Int. 2012 Oct;82(8):840-56. doi: 10.1038/ki.2012.280. Epub 2012 Aug 15. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary change of plasma concentration of Tacrolimus Study the plasma concentration of Tacrolimus in patients with nephrotic syndrome at 0hour,2hours,4hours,6hours,9hours,12hours after oral administration
Secondary Genotypes as measured by next generation sequencing Genotypes as measured by next generation sequencing one week
See also
  Status Clinical Trial Phase
Completed NCT04092725 - Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects Phase 1
Completed NCT04181008 - Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers Early Phase 1
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed NCT04406415 - Oral Nafamostat in Healthy Volunteers Phase 1
Not yet recruiting NCT05421312 - Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip Phase 4
Completed NCT02534753 - A Pharmacokinetics Study of Intravenous Ascorbic Acid Phase 1
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01682408 - Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability Phase 1
Completed NCT01976078 - Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents N/A
Completed NCT01214941 - Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol Phase 4
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01208155 - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets Phase 1
Completed NCT01260025 - Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor Phase 1
Completed NCT00983242 - Drug-Drug Interaction Between Colchicine and Verapamil ER Phase 1
Completed NCT00746499 - Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women. Phase 1
Completed NCT00747721 - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU Phase 1
Completed NCT00984009 - A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice Phase 1
Completed NCT00856570 - A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects Phase 1
Completed NCT01276119 - The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males Phase 1
Completed NCT00730145 - A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis Phase 1